Trotabresib

Cat. No.:	HY-137573
CAS No.:	1706738-98-8
Molecular Formula:	$C_{21}H_{21}NO_4S$
Molecular Weight:	383.46
Target:	Epigenetic Reader Domain
Pathway:	Epigenetics
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (130.39 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.6078 mL	13.0392 mL	26.0783 mL
	5 mM	0.5216 mL	2.6078 mL	5.2157 mL
	10 mM	0.2608 mL	1.3039 mL	2.6078 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (5.42 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

CC-90010 (compound 1) is a reversible and orally active BET inhibitor. CC-90010 is applied in the study for advanced solid tumors[1][2].

CUSTOMER VALIDATION

- Mol Cancer Res. 2023 Jun 6;MCR-22-0916.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. CELGENE QUANTICEL RESEARCH, INC. PROCESS FOR THE PREPARATION OF BROMODOMAIN INHIBITOR. Patent. WO2020023438.

[2]. V. Moreno, et al. CC-90010, a reversible, oral bromodomain and extra-terminal (BET) inhibitor in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory (R/R) non-Hodgkin lymphoma: Updated results of a phase I study.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA